Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 104 articles:
HTML format

Single Articles

    January 2023
  1. KURIMOTO N, Nishida Y, Hosomi S, Itani S, et al
    Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing.
    PLoS One. 2023;18:e0280252.
    PubMed     Abstract available

  2. Expression of Concern: Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam.
    PLoS One. 2023;18:e0280122.

  3. LEE C, Kim S, Kim B, Holzapfel WH, et al
    Disturbance of lipid metabolism in germ-free mice transplanted with gut microbiota of DSS-induced colitis mice.
    PLoS One. 2023;18:e0280850.
    PubMed     Abstract available

  4. NISHIO M, Kunisaki R, Shibata W, Ajioka Y, et al
    Serrated polyps in patients with ulcerative colitis: Unique clinicopathological and biological characteristics.
    PLoS One. 2023;18:e0282204.
    PubMed     Abstract available

  5. RUDRAPATNA VA, Cheng YW, Feuille C, Mosenia A, et al
    Creation of an ustekinumab external control arm for Crohn's disease using electronic health records data: A pilot study.
    PLoS One. 2023;18:e0282267.
    PubMed     Abstract available

  6. ZONG W, Patel A, Chang V, Mitchel EB, et al
    Clinical and lifestyle patterns in Asian children with inflammatory bowel disease in the U.S.
    PLoS One. 2023;18:e0281949.
    PubMed     Abstract available

  7. SCHORLING E, Lick S, Steinberg P, Bruggemann DA, et al
    Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis.
    PLoS One. 2023;18:e0283865.
    PubMed     Abstract available

  8. TANI M, Shinzaki S, Asakura A, Tashiro T, et al
    Seasonal variations in gut microbiota and disease course in patients with inflammatory bowel disease.
    PLoS One. 2023;18:e0283880.
    PubMed     Abstract available

  9. HASAN N, Yang H
    Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models.
    PLoS One. 2023;18:e0285613.
    PubMed     Abstract available

  10. ICHIMIYA T, Kazama T, Ishigami K, Yokoyama Y, et al
    Application of plasma alternative to serum for measuring leucine-rich alpha2-glycoprotein as a biomarker of inflammatory bowel disease.
    PLoS One. 2023;18:e0286415.
    PubMed     Abstract available

  11. DONG F, Kern I, Weidner J, Kugler K, et al
    Clinical course of new-onset Crohn's disease in children and adolescents in dependency of age, initial location, initial severity level and therapy over the period 2000-2014 based on the Saxon Pediatric IBD-Registry in Germany.
    PLoS One. 2023;18:e0287860.
    PubMed     Abstract available

  12. NAGAHORI M, Imai T, Nakashoji M, Tairaka A, et al
    A web-based survey on self-management for patients with inflammatory bowel disease in Japan.
    PLoS One. 2023;18:e0287618.
    PubMed     Abstract available

  13. HATAMNEJAD MR, Shirvani M, Pourhoseingholi MA, Balaii H, et al
    Translation and cross-cultural adaptation of the Persian version of inflammatory bowel disease-fatigue (IBD-F) self-assessment questionnaire.
    PLoS One. 2023;18:e0288592.
    PubMed     Abstract available

  14. PATRA R, Dey AK, Mukherjee S
    Identification of genes critical for inducing ulcerative colitis and exploring their tumorigenic potential in human colorectal carcinoma.
    PLoS One. 2023;18:e0289064.
    PubMed     Abstract available

  15. LIN A, Tan Y, Chen J, Liu X, et al
    Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis.
    PLoS One. 2023;18:e0289021.
    PubMed     Abstract available

  16. OTAKE-KASAMOTO Y, Shinzaki S, Hiyama S, Tashiro T, et al
    Carbon dioxide insufflation reduces the relapse of ulcerative colitis after colonoscopy: A randomized controlled trial.
    PLoS One. 2023;18:e0290329.
    PubMed     Abstract available

  17. LIU Y, Zhang YZ, Imoto S
    Microbial Gene Ontology informed deep neural network for microbe functionality discovery in human diseases.
    PLoS One. 2023;18:e0290307.
    PubMed     Abstract available

  18. MEUNIER M, Spillmann A, Rousseaux C, Schwamborn K, et al
    An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease.
    PLoS One. 2023;18:e0283489.
    PubMed     Abstract available

  19. KAZAMA T, Ando K, Ueno N, Fujiya M, et al
    Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study.
    PLoS One. 2023;18:e0288393.
    PubMed     Abstract available

  20. SAKOWITZ S, Bakhtiyar SS, Mallick S, Khoraminejad B, et al
    Decreasing rates of colectomy for benign neoplasms: A nationwide analysis.
    PLoS One. 2023;18:e0293389.
    PubMed     Abstract available

  21. CHAE K, Seo YS, Yu YM, Chang MJ, et al
    An indirect comparison of efficacy including histologic assessment and safety in biologic therapy in ulcerative colitis: Systemic review and network meta-analysis.
    PLoS One. 2023;18:e0293655.
    PubMed     Abstract available

  22. OTT A, Tutdibi E, Goedicke-Fritz S, Schope J, et al
    Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease.
    PLoS One. 2023;18:e0288147.
    PubMed     Abstract available

  23. KONECNY AJ, Shows DM, Lord JD
    Colonic mucosal associated invariant T cells in Crohn's disease have a diverse and non-public T cell receptor beta chain repertoire.
    PLoS One. 2023;18:e0285918.
    PubMed     Abstract available

  24. WASSERBAUER M, Mala S, Stechova K, Hlava S, et al
    Dysfunction of peripheral somatic and autonomic nervous system in patients with severe forms of Crohn's disease on biological therapy with TNFalpha inhibitors-A single center study.
    PLoS One. 2023;18:e0294441.
    PubMed     Abstract available

    January 2022
  25. PARK J, Yoon H, Shin CM, Park YS, et al
    Clinical factors to predict flare-up in patients with inflammatory bowel disease during international air travel: A prospective study.
    PLoS One. 2022;17:e0262571.
    PubMed     Abstract available

  26. BAKER KA, Miller TD, Marino FE, Hartmann TE, et al
    The exercise-induced inflammatory response in inflammatory bowel disease: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0262534.
    PubMed     Abstract available

  27. LAI HC, Chou JW, Wu YH, Huang PJ, et al
    ABO blood type and clinical characteristics of patients with ulcerative colitis: A hospital-based study in central Taiwan.
    PLoS One. 2022;17:e0260018.
    PubMed     Abstract available

  28. XU F, Wheaton AG, Liu Y, Greenlund KJ, et al
    Major ambulatory surgery among US adults with inflammatory bowel disease, 2017.
    PLoS One. 2022;17:e0264372.
    PubMed     Abstract available

  29. GARDINER LJ, Carrieri AP, Bingham K, Macluskie G, et al
    Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease.
    PLoS One. 2022;17:e0263248.
    PubMed     Abstract available

  30. TONG G, Qian H, Li D, Li J, et al
    Establishment and evaluation of a specific antibiotic-induced inflammatory bowel disease model in rats.
    PLoS One. 2022;17:e0264194.
    PubMed     Abstract available

  31. SAETERSTAD S, Ostvik AE, Royset ES, Bakke I, et al
    Profound gene expression changes in the epithelial monolayer of active ulcerative colitis and Crohn's disease.
    PLoS One. 2022;17:e0265189.
    PubMed     Abstract available

  32. YAO J, Fekadu G, Jiang X, You JHS, et al
    Telemonitoring for patients with inflammatory bowel disease amid the COVID-19 pandemic-A cost-effectiveness analysis.
    PLoS One. 2022;17:e0266464.
    PubMed     Abstract available

  33. LEE SH, Veeriah V, Levine F
    A potent HNF4alpha agonist reveals that HNF4alpha controls genes important in inflammatory bowel disease and Paneth cells.
    PLoS One. 2022;17:e0266066.
    PubMed     Abstract available

  34. NGUYEN TB, Do DN, Nguyen TTP, Nguyen TL, et al
    Immune-related biomarkers shared by inflammatory bowel disease and liver cancer.
    PLoS One. 2022;17:e0267358.
    PubMed     Abstract available

  35. WAKAI M, Hayashi R, Ueno Y, Onishi K, et al
    Promoting mechanism of serum amyloid a family expression in mouse intestinal epithelial cells.
    PLoS One. 2022;17:e0264836.
    PubMed     Abstract available

  36. SHEU NW, Huang SH, Wu DC, Kao JY, et al
    Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus.
    PLoS One. 2022;17:e0265323.
    PubMed     Abstract available

  37. WEDENOJA S, Saarikivi A, Malkonen J, Leskinen S, et al
    Fecal microbiota in congenital chloride diarrhea and inflammatory bowel disease.
    PLoS One. 2022;17:e0269561.
    PubMed     Abstract available

  38. HIGUCHI N, Hiraga H, Sasaki Y, Hiraga N, et al
    Automated evaluation of colon capsule endoscopic severity of ulcerative colitis using ResNet50.
    PLoS One. 2022;17:e0269728.
    PubMed     Abstract available

  39. WANG J, Kou F, Han X, Shi L, et al
    Inflammatory bowel disease and risk of idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis.
    PLoS One. 2022;17:e0270297.
    PubMed     Abstract available

  40. OZAKA S, Sonoda A, Ariki S, Minata M, et al
    Saireito, a Japanese herbal medicine, alleviates leaky gut associated with antibiotic-induced dysbiosis in mice.
    PLoS One. 2022;17:e0269698.
    PubMed     Abstract available

  41. DAS B, Rabalais J, Kozan P, Lu T, et al
    The effect of a fennel seed extract on the STAT signaling and intestinal barrier function.
    PLoS One. 2022;17:e0271045.
    PubMed     Abstract available

  42. HANSEN TM, Nugent Z, Bernstein CN, Samadder NJ, et al
    Characteristics of colorectal cancer and use of colonoscopy before colorectal cancer diagnosis among individuals with inflammatory bowel disease: A population-based study.
    PLoS One. 2022;17:e0272158.
    PubMed     Abstract available

  43. WASSERBAUER M, Hlava S, Drabek J, Stovicek J, et al
    Adalimumab biosimilars in the therapy of Crohn s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
    PLoS One. 2022;17:e0271299.
    PubMed     Abstract available

  44. KANG YH, Tucker SA, Quevedo SF, Inal A, et al
    Metabolic analyses reveal dysregulated NAD+ metabolism and altered mitochondrial state in ulcerative colitis.
    PLoS One. 2022;17:e0273080.
    PubMed     Abstract available

  45. WASSERBAUER M, Hlava S, Trojanek M, Stovicek J, et al
    Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.
    PLoS One. 2022;17:e0273612.
    PubMed     Abstract available

  46. BAMBO GM, Shiferaw E, Melku M
    A mean platelet volume in inflammatory bowel disease: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0273417.
    PubMed     Abstract available

  47. KERN I, Schoffer O, Richter T, Kiess W, et al
    Current and projected incidence trends of pediatric-onset inflammatory bowel disease in Germany based on the Saxon Pediatric IBD Registry 2000-2014 -a 15-year evaluation of trends.
    PLoS One. 2022;17:e0274117.
    PubMed     Abstract available

  48. BIANCHI R, Mamadou-Pathe B, von Kanel R, Roth R, et al
    Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients.
    PLoS One. 2022;17:e0274665.
    PubMed     Abstract available

  49. ELAMIR A, Shaker O, Kamal M, Khalefa A, et al
    Expression profile of serum LncRNA THRIL and MiR-125b in inflammatory bowel disease.
    PLoS One. 2022;17:e0275267.
    PubMed     Abstract available

  50. COLLIER AJ, Gomez DE, Monteith G, Plattner BL, et al
    Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study.
    PLoS One. 2022;17:e0276295.
    PubMed     Abstract available

  51. DOTTI I, Mayorgas A, Salas A
    Generation of human colon organoids from healthy and inflammatory bowel disease mucosa.
    PLoS One. 2022;17:e0276195.
    PubMed     Abstract available

  52. THOMAS S, Mercogliano G, Prendergast GC
    Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatment.
    PLoS One. 2022;17:e0276910.
    PubMed     Abstract available

  53. SAHIN M, Erdogan KE, Tekingunduz E
    Correlation between the tissue ghrelin presence, disease activity and laboratory parameters in ulcerative colitis patients; immunohistochemical study.
    PLoS One. 2022;17:e0276065.
    PubMed     Abstract available

  54. JONES K, Kimble R, Baker K, Tew GA, et al
    Effects of structured exercise programmes on physiological and psychological outcomes in adults with inflammatory bowel disease (IBD): A systematic review and meta-analysis.
    PLoS One. 2022;17:e0278480.
    PubMed     Abstract available

  55. MOON SJ, Lee YC, Kim TJ, Kim K, et al
    Effects of temperature, weather, seasons, atmosphere, and climate on the exacerbation of inflammatory bowel diseases: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0279277.
    PubMed     Abstract available

  56. COHEN-MEKELBURG S, Van T, Yu X, Costa DK, et al
    Understanding clinician connections to inform efforts to promote high-quality inflammatory bowel disease care.
    PLoS One. 2022;17:e0279441.
    PubMed     Abstract available

  57. ROB F, Schierova D, Stehlikova Z, Kreisinger J, et al
    Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study.
    PLoS One. 2022;17:e0277576.
    PubMed     Abstract available

    January 2021
  58. KERN I, Schoffer O, Kiess W, Henker J, et al
    Incidence trends of pediatric onset inflammatory bowel disease in the years 2000-2009 in Saxony, Germany-first results of the Saxon Pediatric IBD Registry.
    PLoS One. 2021;16:e0243774.
    PubMed     Abstract available

  59. KONSTANTINIDIS AO, Adamama-Moraitou KK, Pardali D, Dovas CI, et al
    Colonic mucosal and cytobrush sample cytokine mRNA expression in canine inflammatory bowel disease and their correlation with disease activity, endoscopic and histopathologic score.
    PLoS One. 2021;16:e0245713.
    PubMed     Abstract available

  60. NAFTALI T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, et al
    Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.
    PLoS One. 2021;16:e0246871.
    PubMed     Abstract available

  61. REVILLA L, Mayorgas A, Corraliza AM, Masamunt MC, et al
    Multi-omic modelling of inflammatory bowel disease with regularized canonical correlation analysis.
    PLoS One. 2021;16:e0246367.
    PubMed     Abstract available

  62. DING ZH, Xu XP, Wang TR, Liang X, et al
    The prevalence of Helicobacter pylori infection in inflammatory bowel disease in China: A case-control study.
    PLoS One. 2021;16:e0248427.
    PubMed     Abstract available

  63. RANA T, Korolkova OY, Rachakonda G, Williams AD, et al
    Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease.
    PLoS One. 2021;16:e0246393.
    PubMed     Abstract available

  64. ARKTEG CB, Wergeland Sorbye S, Buhl Riis L, Dalen SM, et al
    Real-life evaluation of histologic scores for Ulcerative Colitis in remission.
    PLoS One. 2021;16:e0248224.
    PubMed     Abstract available

  65. TAMAN H, Fenton CG, Anderssen E, Florholmen J, et al
    DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis.
    PLoS One. 2021;16:e0248905.
    PubMed     Abstract available

  66. FURUSE M, Hosomi S, Nishida Y, Itani S, et al
    The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.
    PLoS One. 2021;16:e0250597.
    PubMed     Abstract available

  67. XU F, Park S, Liu Y, Greenlund KJ, et al
    Dietary intake patterns among adults with inflammatory bowel disease in the United States, 2015.
    PLoS One. 2021;16:e0250441.
    PubMed     Abstract available

  68. ISHIDA N, Higuchi T, Miyazu T, Tamura S, et al
    Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease.
    PLoS One. 2021;16:e0250658.
    PubMed     Abstract available

  69. BUSINGYE D, Pollack A, Chidwick K
    Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.
    PLoS One. 2021;16:e0252458.
    PubMed     Abstract available

  70. TREFZER R, Elpeleg O, Gabrusskaya T, Stepensky P, et al
    Characterization of a L136P mutation in Formin-like 2 (FMNL2) from a patient with chronic inflammatory bowel disease.
    PLoS One. 2021;16:e0252428.
    PubMed     Abstract available

  71. YEN HH, Su PY, Huang SP, Wu L, et al
    Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
    PLoS One. 2021;16:e0252286.
    PubMed     Abstract available

  72. SMITH SCL, Banbury C, Zardo D, Cannatelli R, et al
    Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease.
    PLoS One. 2021;16:e0252210.
    PubMed     Abstract available

  73. CAPITANO ML, Jaiswal A, Broxmeyer HE, Pride Y, et al
    A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease.
    PLoS One. 2021;16:e0252805.
    PubMed     Abstract available

  74. KATO M, Sugimoto K, Ikeya K, Takano R, et al
    Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
    PLoS One. 2021;16:e0254548.
    PubMed     Abstract available

  75. ORFEI M, Gasparetto M, Hensel KO, Zellweger F, et al
    Guidance on the interpretation of faecal calprotectin levels in children.
    PLoS One. 2021;16:e0246091.
    PubMed     Abstract available

  76. MADARAME A, Fukuzawa M, Yamauchi Y, Kono S, et al
    Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.
    PLoS One. 2021;16:e0255620.
    PubMed     Abstract available

  77. LEE JM, Jang JH, Ryu JH, Yoo J, et al
    A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease.
    PLoS One. 2021;16:e0255974.
    PubMed     Abstract available

  78. GAN RW, Sun D, Tatro AR, Cohen-Mekelburg S, et al
    Replicating prediction algorithms for hospitalization and corticosteroid use in patients with inflammatory bowel disease.
    PLoS One. 2021;16:e0257520.
    PubMed     Abstract available

  79. ZHANG L, Wu YB, Dai YK, Liu Q, et al
    Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis.
    PLoS One. 2021;16:e0257599.
    PubMed     Abstract available

  80. KARMI N, Bangma A, Spekhorst LM, van Dullemen HM, et al
    Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFalpha therapy in inflammatory bowel disease.
    PLoS One. 2021;16:e0256860.
    PubMed     Abstract available

  81. AL-SADI R, Engers J, Haque M, King S, et al
    Matrix Metalloproteinase-9 (MMP-9) induced disruption of intestinal epithelial tight junction barrier is mediated by NF-kappaB activation.
    PLoS One. 2021;16:e0249544.
    PubMed     Abstract available

  82. CREEMERS RH, Rezazadeh Ardabili A, Jonkers DM, Leers MPG, et al
    Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.
    PLoS One. 2021;16:e0258271.
    PubMed     Abstract available

  83. TAO F, Xing X, Wu J, Jiang R, et al
    Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice.
    PLoS One. 2021;16:e0248482.
    PubMed     Abstract available

  84. MEI Z, Feng Q, Du P, Li B, et al
    Surgical treatment for cryptoglandular and Crohn's perianal fistulas: Protocol of an umbrella review.
    PLoS One. 2021;16:e0251460.
    PubMed     Abstract available

  85. MORAN MM, Wessman P, Rolfson O, Bohl DD, et al
    The risk of revision following total hip arthroplasty in patients with inflammatory bowel disease, a registry based study.
    PLoS One. 2021;16:e0257310.
    PubMed     Abstract available

  86. BIN MASUD S, Jenkins C, Hussey E, Elkin-Frankston S, et al
    Utilizing machine learning with knockoff filtering to extract significant metabolites in Crohn's disease with a publicly available untargeted metabolomics dataset.
    PLoS One. 2021;16:e0255240.
    PubMed     Abstract available

  87. MIYAZAKI C, Katsumasa N, Huang KC, Liu YF, et al
    Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
    PLoS One. 2021;16:e0254807.
    PubMed     Abstract available

  88. WILSON PA, Santos Franco S, He L, Galwey NW, et al
    Transcriptomic effects of rs4845604, an IBD and allergy-associated RORC variant, in stimulated ex vivo CD4+ T cells.
    PLoS One. 2021;16:e0258316.
    PubMed     Abstract available

  89. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    PubMed     Abstract available

  90. PARK HT, Park WB, Kim S, Lim JS, et al
    Revealing immune responses in the Mycobacterium avium subsp. paratuberculosis-infected THP-1 cells using single cell RNA-sequencing.
    PLoS One. 2021;16:e0254194.
    PubMed     Abstract available

  91. WANG J, Bleich RM, Zarmer S, Zhang S, et al
    Long-read sequencing to interrogate strain-level variation among adherent-invasive Escherichia coli isolated from human intestinal tissue.
    PLoS One. 2021;16:e0259141.
    PubMed     Abstract available

  92. MORIKUBO H, Kobayashi T, Fukuda T, Nagahama T, et al
    Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database.
    PLoS One. 2021;16:e0258537.
    PubMed     Abstract available

  93. IRAK K, Bayram M, Cifci S, Sener G, et al
    Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease.
    PLoS One. 2021;16:e0260034.
    PubMed     Abstract available

  94. KHAN IA, Nayak B, Markandey M, Bajaj A, et al
    Differential prevalence of pathobionts and host gene polymorphisms in chronic inflammatory intestinal diseases: Crohn's disease and intestinal tuberculosis.
    PLoS One. 2021;16:e0256098.
    PubMed     Abstract available

  95. ZHANG J, Wang XJ, Wu LJ, Yang L, et al
    Herb-partitioned moxibustion alleviates colonic inflammation in Crohn's disease rats by inhibiting hyperactivation of the NLRP3 inflammasome via regulation of the P2X7R-Pannexin-1 signaling pathway.
    PLoS One. 2021;16:e0252334.
    PubMed     Abstract available

  96. SCHINEIS C, Ullrich A, Lehmann KS, Holmer C, et al
    Microscopic inflammation in ileocecal specimen does not correspond to a higher anastomotic leakage rate after ileocecal resection in Crohn's disease.
    PLoS One. 2021;16:e0247796.
    PubMed     Abstract available

    January 2020
  97. CAI B, Zhou MH, Huang HL, Zhou AC, et al
    Protective effects of citrulline supplementation in ulcerative colitis rats.
    PLoS One. 2020;15:e0240883.
    PubMed     Abstract available

  98. ALLAIS L, Verschuere S, Maes T, De Smet R, et al
    Translational research into the effects of cigarette smoke on inflammatory mediators and epithelial TRPV1 in Crohn's disease.
    PLoS One. 2020;15:e0236657.
    PubMed     Abstract available

  99. NISHIDA Y, Hosomi S, Yamagami H, Fujimoto K, et al
    Novel prognostic biomarkers of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: Neutrophil-to-lymphocyte ratio.
    PLoS One. 2020;15:e0241322.
    PubMed     Abstract available

  100. UCHIYAMA K, Takami S, Suzuki H, Umeki K, et al
    Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: An investigator-initiated multicenter double-blind clinical trial.
    PLoS One. 2020;15:e0241337.
    PubMed     Abstract available

  101. HOFFMANN P, Behnisch R, Gsenger J, Schnitzler P, et al
    Hepatitis E seroprevalence in a German cohort of patients with inflammatory bowel diseases.
    PLoS One. 2020;15:e0239825.
    PubMed     Abstract available

  102. LIMSRIVILAI J, Lee CK, Prueksapanich P, Harinwan K, et al
    Validation of models using basic parameters to differentiate intestinal tuberculosis from Crohn's disease: A multicenter study from Asia.
    PLoS One. 2020;15:e0242879.
    PubMed     Abstract available

  103. DOMENIS R, Marino M, Cifu A, Scardino G, et al
    Circulating exosomes express alpha4beta7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    PLoS One. 2020;15:e0242342.
    PubMed     Abstract available

  104. LI LN, Liu Y, Zhang HC, Wu T, et al
    Helicobacter pylori infection reduces TAMs infiltration in a mouse model of AOM/DSS induced colitis-associated cancer.
    PLoS One. 2020;15:e0241840.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.